EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 82, Issue 1, Pages 3-18
Publisher
BMJ
Online
2022-11-11
DOI
10.1136/ard-2022-223356
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge
- (2022) Alina Dima et al. Therapeutic Advances in Musculoskeletal Disease
- EULAR 75-year anniversary: commentaries on key ARD papers from 1947
- (2022) Tore K Kvien ANNALS OF THE RHEUMATIC DISEASES
- Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial
- (2022) Maarten Boers et al. ANNALS OF THE RHEUMATIC DISEASES
- Greetings from the editor
- (2022) Josef S Smolen ANNALS OF THE RHEUMATIC DISEASES
- Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy
- (2022) Andrea Amstad et al. RHEUMATOLOGY
- American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
- (2022) Paul Studenic et al. ANNALS OF THE RHEUMATIC DISEASES
- Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis
- (2022) Lotte van Ouwerkerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Andreas Kerschbaumer et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Sytske Anne Bergstra et al. ANNALS OF THE RHEUMATIC DISEASES
- Non‐serious infections in patients with rheumatoid arthritis; results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
- (2021) Katie Bechman et al. Arthritis & Rheumatology
- POS1412 IDENTIFYING HIGH-COST DRUGS FOR RARE RHEUMATIC DISEASES IN ROUTINELY COLLECTED NHS DATA. RESULTS FROM A PILOT STUDY OF RITUXIMAB USE IN VASCULITIS USING DATA FROM THE NATIONAL DISEASE REGISTRATION SERVICE AND THE REGISTRATION OF COMPLEX RARE DISEASES-EXEMPLARS IN RHEUMATOLOGY (RECORDER) PROJECT
- (2021) C. Godsave et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
- (2021) György Nagy et al. ANNALS OF THE RHEUMATIC DISEASES
- Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis
- (2021) Anthony James Ocon et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
- (2021) Imke Redeker et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0481 PATIENT’S PERSPECTIVE ON PATIENT EDUCATION IN AXIAL SPONDYLOARTHRITIS: A QUALITATIVE STUDY
- (2021) Y. M. van der Kraan et al. ANNALS OF THE RHEUMATIC DISEASES
- 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
- (2021) Liana Fraenkel et al. ARTHRITIS CARE & RESEARCH
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
- (2020) Sofia Ramiro et al. ANNALS OF THE RHEUMATIC DISEASES
- Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?
- (2020) Paul Studenic et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
- (2020) Andreas Kerschbaumer et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2020) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
- (2020) Elise van Mulligen et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR definition of difficult-to-treat rheumatoid arthritis
- (2020) György Nagy et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: A meta-analysis of observational studies
- (2020) Wenhui Xie et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial
- (2020) Merete Lund Hetland et al. BMJ-British Medical Journal
- Impact of patient global assessment on achieving remission in patients with rheumatoid arthritis: a multinational study using the METEOR database
- (2019) Ricardo J. O. Ferreira et al. ARTHRITIS CARE & RESEARCH
- Risk profiling for a refractory course of rheumatoid arthritis
- (2019) Manuel Bécède et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
- (2019) Jon T. Giles et al. Arthritis & Rheumatology
- Low Persistence Rates in Rheumatoid Arthritis Patients Treated with Triple Therapy are Attributed to Adverse Drug Events Associated with Sulfasalazine
- (2018) Daniel P. Erhardt et al. ARTHRITIS CARE & RESEARCH
- Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
- (2017) Josef S. Smolen et al. Arthritis & Rheumatology
- Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
- (2016) A Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- 2016 update of the EULAR recommendations for the management of early arthritis
- (2016) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
- (2016) Josef S Smolen et al. LANCET
- Brief Report: Estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
- (2016) Roy Fleischmann et al. Arthritis & Rheumatology
- Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
- (2015) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
- (2014) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
- (2014) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
- (2014) Gerd-Rűdiger Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Sustained Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Patients with Rheumatoid Arthritis
- (2013) L. Aguilar-Lozano et al. JOURNAL OF RHEUMATOLOGY
- Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
- (2013) Josef S Smolen et al. LANCET
- Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients
- (2012) Sophie Martin Du Pan et al. ANNALS OF THE RHEUMATIC DISEASES
- Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions
- (2012) Paul Studenic et al. ANNALS OF THE RHEUMATIC DISEASES
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
- (2012) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
- (2012) M. E. Weinblatt et al. RHEUMATOLOGY
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
- (2011) D. T. Felson et al. ANNALS OF THE RHEUMATIC DISEASES
- Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
- (2010) S. L. Gorter et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) D. Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants
- (2010) Josef S. Smolen et al. ARTHRITIS AND RHEUMATISM
- AGREE II: advancing guideline development, reporting and evaluation in health care
- (2010) M. C. Brouwers et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries
- (2010) Jeffrey R. Curtis et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- Malignancy and biologic therapy in rheumatoid arthritis
- (2008) Johan Askling et al. CURRENT OPINION IN RHEUMATOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now